Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia On The Move: Personnel News From AstraZeneca, Novartis, Teva

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca Japan appoints a 38-year old president, Novartis Japan selects a woman CEO and Teva recruits a Lilly veteran to head its operation in Japan. These moves and others are profiled in this edition of Asia On The Move.

You may also be interested in...



World First Or Beating The US? China Ups COVID-19 Vaccines Game

Touting its coronavirus vaccines as a "global public good", China is quietly preparing for the first general approvals and launches, possibly within weeks, developers say. But who will be first in line to receive them? And at what cost? Distribution and pricing are just some of the unanswered questions.

New Designations Set To Speed Hemlibra, CAR-T In China

China is set to grant priority reviews to major biologics from Roche, the first CAR-T therapy from Wuxi Juno, and breakthrough therapy designation to a pediatric respiratory antiviral from ArkBio.

China Proposes 12 Months Exclusivity For First Generics

China’s National Medical Products Administration has released key regulations and proposals designed to encourage first generics through a 12-month market exclusivity proposal.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel